US Broker Ratings

Dianthus Therapeutics, Inc. (DNTH) Investor Outlook: Analyzing the 70.55% Potential Upside

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a biotechnology firm specializing in innovative therapies for autoimmune and inflammatory diseases, has caught the attention of investors with a compelling..

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: A Deep Dive into Potential 182.62% Upside

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) stands out in the biotechnology sector with its innovative approach to drug development. With a market capitalization of $550.2 million, this..

OrthoPediatrics Corp. (KIDS) Investor Outlook: Navigate a 47% Potential Upside with Expert Insights

For investors eyeing the healthcare sector, OrthoPediatrics Corp. (NASDAQ: KIDS) presents an intriguing opportunity, bolstered by a consensus of bullish analyst ratings and a notable potential..

Weave Communications, Inc. (WEAV) Stock Analysis: Exploring a 56% Potential Upside Amidst Healthcare Innovation

Weave Communications, Inc. (NASDAQ: WEAV) is capturing attention in the healthcare technology sector with its innovative software solutions tailored for small and medium-sized businesses. With a..

Syndax Pharmaceuticals (SNDX) Stock Analysis: A Biotech Gem with 164% Upside Potential

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) has emerged as a compelling entity in the biotechnology sector, capturing investor attention with its promising pipeline and substantial growth prospects...

Keros Therapeutics, Inc. (KROS) Stock Analysis: Unpacking a 42% Potential Upside

Keros Therapeutics, Inc. (NASDAQ: KROS) has been capturing investor attention with a striking potential upside of 42.24%, as indicated by its average target price of $23.00...

AnaptysBio, Inc. (ANAB)

❌ Error generating article: Server error: `POST https://api.openai.com/v1/chat/completions` resulted in a `520 ` response: error code: 520

..

Owens & Minor, Inc. (OMI) Stock Analysis: Navigating a Challenging Market with an 82.69% Potential Upside

Owens & Minor, Inc. (NYSE: OMI) presents a compelling, albeit challenging, investment opportunity for those keen on the healthcare sector. With a focus on medical distribution,..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Unraveling a 115% Potential Upside with Strong Buy Ratings

ArriVent BioPharma, Inc. (NASDAQ: AVBP) is capturing the attention of the investment community with its promising drug development pipeline and an impressive potential upside of 115.09%...

Trevi Therapeutics, Inc. (TRVI) Investor Outlook: An 87% Potential Upside Sparks Interest in Biotech Innovator

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is capturing investor attention with a compelling potential upside of 87.10%, according to analyst ratings. This clinical-stage biopharmaceutical company, headquartered in..

Cogent Biosciences, Inc. (COGT) Investor Outlook: Exploring a Potential 56% Upside in Biotech Innovation

Cogent Biosciences, Inc. (COGT), a dynamic player in the biotechnology sector, is capturing attention with its precision therapies aimed at genetically defined diseases. With a market..

AbCellera Biologics Inc. (ABCL) Stock Analysis: A Potential 106% Upside Awaits Investors

AbCellera Biologics Inc. (NASDAQ: ABCL), a prominent player in the biotechnology sector, is drawing attention with its impressive potential upside of 106.03%, according to analyst ratings...

iRadimed Corporation (IRMD) Stock Analysis: Exploring Growth Potential in the Medical Devices Sector

iRadimed Corporation (NASDAQ: IRMD), a prominent player in the medical devices industry, has been making notable strides in the healthcare sector with its innovative MRI-compatible products...

Savara, Inc. (SVRA) Stock Analysis: Uncovering a 159% Upside Potential in Biotech

Savara, Inc. (NASDAQ: SVRA) presents a compelling opportunity for investors keen on exploring the high-risk, high-reward world of biotechnology. With a market capitalization of $801.19 million,..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: Biotechnology Innovator with 54.40% Potential Upside

Arcus Biosciences, Inc. (NASDAQ: RCUS) stands out in the biotechnology sector with its focus on developing innovative cancer therapies. Headquartered in Hayward, California, the company has..

Zymeworks Inc. (ZYME) Stock Analysis: Exploring a 36% Potential Upside in the Biotech Sector

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company, is making headlines with a compelling potential upside of 36.62%. This potential gain is sparking investor interest, particularly..

SI-BONE, Inc. (SIBN) Stock Analysis: Exploring a 63% Potential Upside in the Medical Devices Sector

SI-BONE, Inc. (NASDAQ: SIBN), a prominent player in the healthcare sector’s thriving medical devices industry, has garnered significant attention from investors, not only for its innovative..

Sionna Therapeutics, Inc. (SION) Stock Analysis: Healthcare Innovator with a 10.47% Potential Upside

Sionna Therapeutics, Inc. (SION), a clinical-stage biopharmaceutical company, is drawing investor attention with its pipeline of promising cystic fibrosis treatments and a notable 10.47% potential upside...

Xeris Biopharma Holdings, Inc. (XERS): Growth Potential and Analyst Enthusiasm Signal a Promising Investment Opportunity

As a dynamic player in the biotechnology sector, Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is garnering attention with its innovative approach to treating chronic endocrine and..

Akebia Therapeutics (AKBA) Investor Outlook: Exploring a Potential 188% Upside

Akebia Therapeutics, Inc. (NASDAQ: AKBA) stands out in the biopharmaceutical sector with its focus on developing treatments for kidney diseases. The company, headquartered in Cambridge, Massachusetts,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds